The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis.

The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis.

Raythatha, Jigar;Arnold, Lauren;
epigenomics 2019 Vol. 11 pp. 1553-1555
319
raythatha2019theepigenomics

Abstract

Jigar Raythatha has spent nearly 20 years in the biotechnology industry in a variety of business functions. He rejoined Constellation in March 2017 as the company's Chief Executive Officer, from Jounce Therapeutics, where he held the role of the Chief Business Officer. At Jounce, Jigar was the first employee and helped build the company from its inception to a 100-person, publicly traded research and development organization. Previously, he served as the head of the corporate development at Constellation, where he led business development, strategy, and program and alliance management functions. Prior to his first stint at Constellation, Jigar worked with Red Abbey Venture Partners. Earlier in his career, Jigar held roles of increasing responsibility at Biogen and A.T. Kearney. He earned an MBA from Columbia University and a BA in biochemistry and economics from Rutgers University.

Citation

ID: 67530
Ref Key: raythatha2019theepigenomics
Use this key to autocite in SciMatic or Thesis Manager

References

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
67530
Unique Identifier:
10.2217/epi-2019-0274
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet

Saymatik Web3.0 Wallet